Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB264 + Osimertinib in 1L EGFR-mutated Advanced Non-Squamous NSCLC
NCT06670196Phase 3Active, not recruiting
- Sponsor
- Kelun-Biotech
- Start
- Nov 2024
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Kelun-Biotech. Primary endpoint: Progression-Free Survival at 36 months. Started Nov 2024; status: active, not recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06670196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06670196.